Americans Overpaying for Cancer Drugs
Compared to countries in Europe and elsewhere, people in the U.S. pay a significantly higher price for a common cancer drug, according to an independent study at Britain’s University of Liverpool
Specifically, the study found that the cost of tyrosine kinase inhibitors (TKIs), a potent class of cancer pills with fewer side effects than chemotherapy, is almost double in the U.S. compared to what it is in many other countries.
Researchers calculated that with large-scale production, treatment prices of the medications could range from $150 to $4,022 per person a year. Currently prices range from $75,000 to $100,000 a year.
Drug companies argue that they need to make decent profits to pay for the billions of dollars needed for drug research. Many companies also have extensive low-cost or even free access schemes for patients who cannot afford their medicines.
But the high prices charged for modern drugs is generating increasing push-back from healthcare providers, patients and some doctors.